Positive results with RXi-109 for dermal scarring in trial
Published
18th Jan 2018
RXi Pharmaceuticals has announced positive results with its lead clinical compound RXI- 109 in a Phase II clinical trial on the outcome of scar revision surgery for hypertrophic scars in healthy adults. The primary effectiveness objective was met as shown by a statistically significant improved visual appearance of revised scars after scar revision surgery and treatment with RXI-109 versus control. The full study results show that the product was safe and well tolerated for all dosage groups.
